Communiqués Entrada Therapeutics, Inc.

Actions

TRDA

US29384C1080

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
7,570 ^USD	-0,39%		+1,47%	-26,36%

05/08	Entrada Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
03/08	Entrada Therapeutics : un initié cède pour 807 027 $ d'actions, selon un récent document de la SEC	MT

Communiqués

05/08	Entrada Therapeutics Reports Second Quarter 2026 Financial Results	GL
05/08	Entrada Therapeutics Reports Second Quarter 2026 Financial Results	AQ
02/06	Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics’ ELEVATE-45-201 Study	GL
01/06	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
07/05	Entrada Therapeutics : Corporate Presentation May 2026	PU
07/05	Entrada Therapeutics Reports First Quarter 2026 Financial Results	GL
07/05	Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study	GL
07/05	Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study	AQ
06/05	Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026	GL
07/04	Entrada Therapeutics : Corporate Presentation April 2026	PU
02/03	Entrada Therapeutics : Corporate Presentation March 2026	PU
02/03	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
02/03	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
26/02	Entrada Therapeutics : Corporate Presentation February 2026	PU
26/02	Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results	GL
18/02	Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics ELEVATE-44-201 Study	AQ
17/02	Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study	GL
04/02	Entrada Therapeutics to Present at Upcoming Investor Conferences	GL
08/01	Entrada Therapeutics : Corporate Presentation January 2025	PU
08/01	Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases	GL
17/12	Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	GL
15/12	Entrada Therapeutics : Corporate Presentation December 2025	PU
04/12	Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	GL
06/11	Entrada Therapeutics : Corporate Presentation November 2025	PU
06/11	Entrada Therapeutics Reports Third Quarter 2025 Financial Results	GL